1. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134(6):1682-98. [
DOI:10.1053/j.gastro.2008.02.077] [
PMID]
2. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-62. [
DOI:10.1002/hep.23312] [
PMID]
3. Ludwig J, Viggiano TR, Mcgill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):432-8.
4. Hormati A, Shakeri M, Iranikhah A, Afifian M, Sarkeshikian SS. Non-alcoholic fatty liver disease. Govaresh. 2018;23(4):03-15.
5. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. 18 ed: McGraw Hill Professional; 2012.
6. Moghaddasifar I, Lankarani KB, Moosazadeh M, et al. Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. Int J Organ Transplant Med. 2016;7(3):149-60.
7. Seyedian SS, Hajiani E, Hashemi SJ, et al. Relationship between serum ferritin level and transient elastography findings among patients with nonalcoholic fatty liver disease. J Family Med Primary Care. 2017;6(4):750. [
DOI:10.4103/jfmpc.jfmpc_158_17] [
PMID] [
PMCID]
8. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. J Lab Clin Med. 2017;183:57-70. [
DOI:10.1016/j.trsl.2017.01.001] [
PMID] [
PMCID]
9. Edwardson CL, Gorely T, Davies MJ, et al. Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PloS one. 2012;7(4):e34916. [
DOI:10.1371/journal.pone.0034916] [
PMID] [
PMCID]
10. Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome. Endocrinol Nutr. 2013;60:39-43. [
DOI:10.1016/S1575-0922(13)70026-3]
11. Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark edition). 2021;26:206-37. [
DOI:10.2741/4892] [
PMID] [
PMCID]
12. Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-32. [
DOI:10.1016/B978-0-12-387042-1.00006-X] [
PMID]
13. Iranikhah A, Hormati A, Shakeri M, Aghaali M. Non-alcoholic fatty liver disease in Children. J Mazandaran Univ Med Sci. 2018;28(165):230-42.
14. Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Therap. 2013;37(7):720-9. [
DOI:10.1111/apt.12255] [
PMID]
15. Adams LA, Crawford DH, Stuart K, et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology. 2015;61(5):1555-64. [
DOI:10.1002/hep.27662] [
PMID]
16. Fernández-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. lancet Diabet Endocrinol. 2014;2(6):513-26. [
DOI:10.1016/S2213-8587(13)70174-8]
17. Ryan JD, Marjot T, Cobbold JF. Does the death knell toll for phlebotomy in NAFLD? Hepatology. 2015;62(6):1920-1. [
DOI:10.1002/hep.28029] [
PMID]
18. Valenti L, Fracanzani A, Dongiovanni P, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol. 2014;20(11):3002-10. [
DOI:10.3748/wjg.v20.i11.3002] [
PMID] [
PMCID]
19. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85. [
DOI:10.1111/j.1365-2036.2011.04724.x] [
PMID]
20. Kim MJ, Mitchell DG, Ito K, Hann HW, Park YN, Kim PN. Hepatic iron deposition on MR imaging in patients with chronic liver disease: correlation with serial serum ferritin concentration. Abdom Image. 2001;26(2):149-56. [
DOI:10.1007/s002610000121] [
PMID]
21. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96(8):2448-55. [
DOI:10.1111/j.1572-0241.2001.04052.x] [
PMID]
22. Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2012;55(1):77-85. [
DOI:10.1002/hep.24706] [
PMID] [
PMCID]
23. Beaton MD, Chakrabarti S, Adams PC. Inflammation is not the cause of an elevated serum ferritin in non-alcoholic fatty liver disease. Ann Hepatol. 2014;13(3):353-6. [
DOI:10.1016/S1665-2681(19)30864-6]
24. Sartori M, Andorno S, Rossini A, et al. Phlebotomy improves histology in chronic hepatitis C males with mild iron overload. World J Gastroenterol. 2010;16(5):596-602. [
DOI:10.3748/wjg.v16.i5.596] [
PMID] [
PMCID]
25. Girelli CM, Mirata C, Casiraghi A. Effect of blood letting on serum aminotransferase levels of patients with chronic hepatitis C and iron overload. Recenti Prog Med. 1998;89(5):241-4.
26. Jaruvongvanich V, Riangwiwat T, Sanguankeo A, Upala S. Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis. Saudi J Gastroenterol. 2016;22(6):407-14. [
DOI:10.4103/1319-3767.195551] [
PMID] [
PMCID]
27. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007;102(6):1251-8. [
DOI:10.1111/j.1572-0241.2007.01192.x] [
PMID]
28. Valenti L, Fracanzani AL, Dongiovanni P, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol. 2014;20(11):3002-10. [
DOI:10.3748/wjg.v20.i11.3002] [
PMID] [
PMCID]
29. Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. QJM. 2011;104(2):141-9. [
DOI:10.1093/qjmed/hcq170] [
PMID]
30. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659-68. [
DOI:10.1001/jama.2011.520] [
PMID] [
PMCID]
31. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792-8. [
DOI:10.1002/hep.22429] [
PMID]
32. Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77-85. [
DOI:10.1002/hep.24706] [
PMID] [
PMCID]
33. J O'Brien, LW Powell. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6(1):332-41. [
DOI:10.1007/s12072-011-9304-9] [
PMID]
34. Khodadoostan M, Zamanidoost M, Shavakhi A, Sanei H, Shahbazi M, Ahmadian M. Effects of phlebotomy on liver enzymes and histology of patients with nonalcoholic fatty liver disease. Adv Biomed Res. 2017;6:12. [
DOI:10.4103/2277-9175.200787] [
PMID] [
PMCID]
35. Bai CH, Wu MS, Owaga E, Cheng SY, Pan WH, Chang JS. Relationship between hemoglobin levels and risk for suspected non-alcoholic fatty liver in Taiwanese adults. Chin J Physiol. 2014;57(5):286-94. [
DOI:10.4077/CJP.2014.BAD280] [
PMID]
36. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122(4):931-9. [
DOI:10.1053/gast.2002.32403] [
PMID]
37. Jaruvongvanich V, Riangwiwat T, Sanguankeo A, Upala S. Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis. Saudi J Gastroenterol. 2016;22(6):407-14. [
DOI:10.4103/1319-3767.195551] [
PMID] [
PMCID]